Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease
Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease
Acumen Pharmicals宣布在早期阿尔茨海默氏病的Sabirnetug(ACU193)的ALTITUDE-AD 2期临床试验中为首位患者服药
Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease
Acumen Pharmicals宣布在早期阿尔茨海默氏病的Sabirnetug(ACU193)的ALTITUDE-AD 2期临床试验中为首位患者服药